The effect of addition of two targeted vectors, cRGD peptide and folic acid, with the same linker length on the properties of the doxorubicin phospholipid composition: a study of properties in vitro
Serious side effects of the chemotherapeutic drug doxorubicin prompt researchers to develop systems for its targeted delivery to cells. In this work, we continued the study on the effect of using two vectors in a phospholipid delivery system of doxorubicin (Dox) for targeted therapy of breast cancer. We have obtained a composition NPh-Dox-cRGD-Fol(2.0) with the same linker length for both targeting ligands, cRGD and folic acid (PEG 2000). The resulting composition NPh-Dox-cRGD-Fol(2.0) with a particle size less than 50 nm and with 99% Dox incorporated into nanoparticles in an experiment on drug release at different pH values (5.0 and 7.4) showed a faster release and a high level of Dox compared to the phospholipid nanoform and a composition containing only the cRGD peptide. In vitro experiments on MDA-MB-231 breast cancer cells expressing the folate receptor and integrin αvβ3 demonstrated an increase in the total accumulation and internalization of Dox upon incubation with the dual-vector composition compared to the control samples. On the MCF-7 breast cancer cell line (expressing only the folate receptor), a similar effect was observed upon incubation with the single-vector composition containing folic acid (NPh-Dox-Fol(2.0)). In experiments with normal Wi-38 cell line, the internalization and total accumulation of the drug were comparable for both the free substance and the vector compositions. After 24 h-incubation of MDA-MB-231 cells with Dox-containing (10 μg/ml DOX) samples, the lowest percentage of living cells was observed for the studied dual-vector composition NPh-Dox-cRGD-Fol(2.0). On MCF-7 cells, the cytotoxic effect was manifested equally for the studied samples. The study of the cell death pathway on MDA-MB-231 cells showed the predominance of the apoptotic pathway (late apoptosis), while in the case of MCF-7 the necrosis pathway predominated. The cell cycle study performed using MDA-MB-231 cells (folate receptor (+) and integrin αvβ3 (+)) revealed an increase in the percentage of cells in the G0/G1 phase was noted thus indicating apoptotic cell death during incubation with NPh-Dox-cRGD-Fol(2.0). No differences were found between the samples in experiments performed on MCF-7 cells (folate receptor (+) and integrin αvβ3 (-)).
Kostryukova L.V., Tereshkina Yu.A., Bedretdinov F.N., Gisina A.M. (2025) The effect of addition of two targeted vectors, cRGD peptide and folic acid, with the same linker length on the properties of the doxorubicin phospholipid composition: a study of properties in vitro. Biomeditsinskaya Khimiya, 71(1), 37-50.
Kostryukova L.V. et al. The effect of addition of two targeted vectors, cRGD peptide and folic acid, with the same linker length on the properties of the doxorubicin phospholipid composition: a study of properties in vitro // Biomeditsinskaya Khimiya. - 2025. - V. 71. -N 1. - P. 37-50.
Kostryukova L.V. et al., "The effect of addition of two targeted vectors, cRGD peptide and folic acid, with the same linker length on the properties of the doxorubicin phospholipid composition: a study of properties in vitro." Biomeditsinskaya Khimiya 71.1 (2025): 37-50.
Kostryukova, L. V., Tereshkina, Yu. A., Bedretdinov, F. N., Gisina, A. M. (2025). The effect of addition of two targeted vectors, cRGD peptide and folic acid, with the same linker length on the properties of the doxorubicin phospholipid composition: a study of properties in vitro. Biomeditsinskaya Khimiya, 71(1), 37-50.
References
Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (2024) The state of oncological care for the population of Russia in 2023; P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, Moscow, pp. 262. Scholar google search
Marshall S.K., Angsantikul P., Pang Z., Nasongkla N., Hussen R.S.D., Thamphiwatana S.D. (2022) Biomimetic targeted theranostic nanoparticles for breast cancer treatment. Molecules, 27(19), 6473. CrossRef Scholar google search
Nicoletto R.E., Ofner C.M. 3rd (2022) Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother. Pharmacol., 89(3), 285–311. CrossRef Scholar google search
Sheibani M., Azizi Y., Shayan M., Nezamoleslami S., Eslami F., Farjoo M.H., Dehpour A.R. (2022) Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches. Cardiovasc. Toxicol., 22(4), 292–310. CrossRef Scholar google search
Kong C.-Y., Guo Z., Song P., Zhang X., Yuan Y.-P., Teng T., Yan L., Tang Q.-Z. (2022) Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int. J. Biol. Sci., 18(2), 760–770. CrossRef Scholar google search
Qin L., Wu L., Jiang S., Yang D., He H., Zhang F., Zhang P. (2018) Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin. J. Drug Target., 26(4), 289–295. CrossRef Scholar google search
Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., Moreira P.I. (2009) Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem., 16(25), 3267–3285. CrossRef Scholar google search
Ansari L., Shiehzadeh F., Taherzadeh Z., Nikoofal-Sahlabadi S., Momtazi-Borojeni A.A., Sahebkar A., Eslami S. (2017) The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther., 24(5), 189–193. CrossRef Scholar google search
Prados J., Melguizo C., Ortiz R., Vélez C., Alvarez P.J., Arias J.L., Ruíz M.A., Gallardo V., Aranega A. (2012) Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med. Chem., 12(9), 1058–1070. CrossRef Scholar google search
Zitzmann S., Ehemann V., Schwab M. (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res., 62(18), 5139–5143. Scholar google search
Tsai C.-C., Yang Y.-C.S.H., Chen Y.-F., Huang L.-Y., Yang Y.-N., Lee S.-Y., Wang W.-L., Lee H.-L., Whang-Peng J., Lin H.-Y., Wang K. (2023) Integrins and actions of androgen in breast cancer cells., 12(17), 2126. CrossRef Scholar google search
Lan K.-C., Wei K.-T., Lin P.-W,. Lin C.-C., Won P.-L., Liu Y.-F., Chen Y.-J., Cheng B.-H., Chu T.M.-G., Chen J.-F., Huang K.-E., Chang C., Kang H.-Y. (2022) Targeted activation of androgen receptor signaling in the periosteum improves bone fracture repair. Cell Death Dis., 13(2), 123. CrossRef Scholar google search
Bogdanowich-Knipp S.J., Jois D.S.S., Siahaan T.J. (1999) The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J. Pept. Res., 53(5), 523–529. CrossRef Scholar google search
Bogdanowich-Knipp S.J., Chakrabarti S., Williams T.D., Dillman R.K., Siahaan T.J. (1999) Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res., 53(5), 530–541. CrossRef Scholar google search
Jiang Y., Wang C., Zhang M., Liu L., Gao X., Zhang S., Ye D. (2023) Study of folate-based carbon nanotube drug delivery systems targeted to folate receptor α by molecular dynamic simulations. Int. J. Biol. Macromol., 244, 125386. CrossRef Scholar google search
Zwick G.L., Mansoori G.A., Jeffery C.J. (2012) Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev., 3, 18496. CrossRef Scholar google search
Mansoori G.A., Brandenburg K.S., Shakeri-Zadeh A. (2010) A comparative study of two folate-conjugated gold nanoparticles for cancer nanotechnology applications. Cancers, 2(4), 1911–1928. CrossRef Scholar google search
Luo W., Wen G., Yang L., Tang J., Wang J., Wang J., Zhang S., Zhang L., Ma F., Xiao L., Wang Y., Li Y. (2017) Dual-targeted and pH-sensitive doxorubicin prodrug-microbubble complex with ultrasound for tumor treatment. Theranostics, 7(2), 452–465. CrossRef Scholar google search
Tereshkina Yu.A., Bedretdinov F.N., Kostryukova L.V. (2023) Two-vector transport phospholipid nanosystem of doxorubicin: accumulation in breast cancer cells in vitro. Biomeditsinskya Khimiya, 69(6), 409–419. CrossRef Scholar google search
Song Z., Lin Y., Zhang X., Feng C., Lu Y., Gao Y., Dong C. (2017) Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects. Int. J. Nanomedicine, 12, 1941–1958. CrossRef Scholar google search
Xu B., Yuan L., Hu Y., Xu Z., Qin J.-J., Cheng X.-D. (2021) Synthesis, characterization, cellular uptake, and in vitro anticancer activity of fullerenol-doxorubicin conjugates. Front. Pharmacol., 11, 598155. CrossRef Scholar google search
Sheldon K., Liu D., Ferguson J., Gariepy J. (1995) Loligomers: design of de novo peptide-based intracellular vehicles. Proc. Natl. Acad. Sci. USA, 92(6), 2056–2060. CrossRef Scholar google search
Wan D., Liu Y., Guo X., Zhang J., Pan J. (2022) Intelligent drug delivery by peptide-based dual-function micelles. Int. J. Mol. Sci., 23(17), 9698. CrossRef Scholar google search
Dinakar Y.H., Karole A., Parvez S., Jain V., Mudavath S.L. (2023) Folate receptor targeted NIR cleavable liposomal delivery system augment penetration and therapeutic efficacy in breast cancer. Biochim. Biophys. Acta Gen. Subj., 1867(9), 130396. CrossRef Scholar google search
Tikhonova E.G., Sanzhakov M.A., Tereshkina Yu.A., Kostryukova L.V., Khudoklinova Yu.Yu., Orlova N.A., Bobrova D.V., Ipatova O.M. (2022) Drug transport system based on phospholipid nanoparticles: production technology and characteristics. Pharmaceutics, 14(11), 2522. CrossRef Scholar google search
Danaei M., Dehghankhold M., Ataei S., Hasanzadeh Davarani F., Javanmard R., Dokhani A., Khorasani S., Mozafari M.R. (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 10(2), 57. CrossRef Scholar google search
Bhattacharjee S. (2016) DLS and zeta potential — What they are and what they are not?. J. Control. Release, 235, 337–351. CrossRef Scholar google search
Meng F., Zhong Y., Cheng R., Deng C., Zhong Z. (2014) pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine, 9(3), 487–499. CrossRef Scholar google search
Gai Y., Jiang Y., Long Y., Sun L., Liu Q., Qin C., Zhang Y., Zeng D., Lan X. (2020) Evaluation of an integrin αvβ3 and aminopeptidase N dual-receptor targeting tracer for breast cancer imaging. Mol. Pharm., 17(1), 349–358. CrossRef Scholar google search
Das D., Koirala N., Li X., Khan N., Dong F., Zhang W., Mulay P., Shrikhande G., Puskas J., Drazba J., McLennan G. (2020) Screening of polymer-based drug delivery vehicles targeting folate receptors in triple-negative breast cancer. J. Vasc. Interv. Radiol., 31(11), 1866–1873.e2. CrossRef Scholar google search
Godugu K., Sudha T., Davis P.J., Mousa S.A. (2021) Nano diaminopropane tetrac and integrin αvβ3 expression in different cancer types: anti-cancer efficacy and safety. Cancer Treat. Res. Commun., 28, 100395. CrossRef Scholar google search
Zagami R., Rapozzi V., Piperno A., Scala A., Triolo C., Trapani M., Xodo L.E., Monsù Scolaro L., Mazzaglia A. (2019) Folate-decorated amphiphilic cyclodextrins as cell-targeted nanophototherapeutics. Biomacromolecules, 20(7), 2530–2544. CrossRef Scholar google search
Yoshida T., Oide N., Sakamoto T., Yotsumoto S., Negishi Y., Tsuchiya S., Aramaki Y. (2006) Induction of cancer cell-specific apoptosis by folate-labeled cationic liposomes. J. Control. Release, 111(3), 325–332. CrossRef Scholar google search
Lanza P., Felding-Habermann B., Ruggeri Z.M., Zanetti M., Billetta R. (1997) Selective interaction of a conformationallyconstrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells. Blood Cells Mol. Dis., 23(2), 230–241. CrossRef Scholar google search
Kostryukova L.V., Tereshkina Y.A., Tikhonova E.G., Khudoklinova Y.Y., Bobrova D.V., Gisina A.M., Morozevich G.E., Pronina V.V., Bulko T.V., Shumyantseva V.V. (2023) Effect of an NGR peptide on the efficacy of the doxorubicin phospholipid delivery system. Nanomaterials, 13(4), 2229. CrossRef Scholar google search
Rivankar S. (2014) An overview of doxorubicin formulations in cancer therapy. J. Cancer Res. Ther., 10(4), 853–858. CrossRef Scholar google search
Feng X., Wu C., Yang W., Wu J., Wang P. (2022) Mechanism-based sonodynamic-chemo combinations against triple-negative breast cancer. Int. J. Mol. Sci., 23(14), 7981. CrossRef Scholar google search
